Literature DB >> 20059601

Acute gout management during hospitalization: a need for a protocol.

S R Gnanenthiran1, G M Hassett, K A Gibson, H P McNeil.   

Abstract

AIM: To review systematically the management of acute gout during hospitalization.
METHODS: Case-file review of all episodes of acute gout occurring in a large tertiary hospital over a 20-month period.
RESULTS: Of 134 acute gout episodes identified, the large majority (118) occurred in patients not admitted under the rheumatology unit. Baseline anti-gout medications were frequently ceased on admission and in 9% of episodes, no pharmacotherapy was prescribed. Delays in initiation of treatment occurred in up to 29% of patients. Acute management included anti-inflammatory monotherapy, or combinations of colchicine, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Of patients prescribed colchicine, 26% received >1.5 mg/day and a strong correlation was found between colchicine dose and the occurrence of diarrhoea. NSAIDs were prescribed in 29% of patients with pre-existing renal impairment. Overall, 25% of patients received inappropriate pharmacological management. In patients not under the direct care of the rheumatology unit, in-hospital rheumatology consultation was sought by the treating unit in 34% of episodes. Consultation was sought more frequently in patients with multiple joint involvement, but there were no other obvious differences in baseline clinical characteristics between cases with or without rheumatology involvement. In cases with rheumatology involvement, patients were investigated more frequently, they received more pharmacotherapeutic intervention, in particular combination anti-inflammatory therapy, and they achieved better symptomatic relief and long-term follow up.
CONCLUSION: Acute gout episodes in hospital are variably investigated and treated with frequent suboptimal management. We recommend establishment of a hospital-wide protocol to support decision-making regarding investigations, treatment and follow up.
© 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College of Physicians.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20059601     DOI: 10.1111/j.1445-5994.2010.02165.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  7 in total

Review 1.  Difficult-to-treat gouty arthritis: a disease warranting better management.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

Review 2.  Inpatient gout: a review.

Authors:  Mark C Fisher; Michael H Pillinger; Robert T Keenan
Journal:  Curr Rheumatol Rep       Date:  2014-11       Impact factor: 4.592

Review 3.  Optimizing current treatment of gout.

Authors:  Frances Rees; Michelle Hui; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2014-03-11       Impact factor: 20.543

4.  ACTH vs steroids for the treatment of acute gout in hospitalized patients: a randomized, open label, comparative study.

Authors:  Andrew P Andonopoulos; Neoklis Georgopoulos; Dimitrios Daoussis; Panagiotis Kordas; George Varelas; Marina Michalaki; Anny Onoufriou; Irene Mamali; George Iliopoulos; Konstantinos Melissaropoulos; Konstantinos Ntelis; Dimitrios Velissaris; Giannis Tzimas; Panagiotis Georgiou; Sofia Vamvakopoulou; Fotini Paliogianni
Journal:  Rheumatol Int       Date:  2022-04-21       Impact factor: 2.631

5.  Gout and comorbidity: a nominal group study of people with gout.

Authors:  Jasvinder A Singh
Journal:  Arthritis Res Ther       Date:  2017-09-15       Impact factor: 5.156

6.  Quality of gout care in the emergency departments: a multicentre study.

Authors:  Patapong Towiwat; Pariwat Phungoen; Kitti Tantrawiwat; Pavita Laohakul; Duangkamol Aiewruengsurat; Chokchai Thanadetsuntorn; Nopparat Ruchakorn; Passagorn Sangsawangchot; Bodin Buttham
Journal:  BMC Emerg Med       Date:  2020-04-20

7.  Improving outcomes for patients hospitalized with gout: a systematic review.

Authors:  Mark D Russell; Benjamin D Clarke; Edward Roddy; James B Galloway
Journal:  Rheumatology (Oxford)       Date:  2021-12-24       Impact factor: 7.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.